Page 69 - Haematologica Vol. 109 - July 2024

ARTICLE - Leukemia-induced interferon signature in stroma M.W.E. Smeets et al.
Disclosures
No conflicts of interest to disclose.
Contributions
MWES performed experiments, collected data, analyzed data, and wrote the paper for this study. EMPS performed Affymetrix gene studies and lentiviral silencing experiments. MWES, EMPS, MLdB, and CvdV designed the study and finalized this manuscript. JO, FS, MMPV, CHJV, and CvdV performed experiments. LS analyzed the RNA sequencing data. SN was responsible for the Luminex assays. All authors reviewed the final manuscript.
Acknowledgments
We would like to thank all group members of the Eras- mus Medical Center in Rotterdam, and Princess Máxima
References
1. Bürgler S, Nadal D. Pediatric precursor B acute lymphoblastic leukemia: are T helper cells the missing link in the infectious etiology theory? Mol Cell Pediatr. 2017;4(1):6.
2. Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018;60(1):4-12.
3. Pastorczak A, Domka K, Fidyt K, Martyna P, Firczuk M. Mechanisms of immune evasion in acute lymphoblastic leukemia. Cancers (Basel). 2021;13(7):1536.
4. Steeghs EMP, Boer JM, Hoogkamer AQ, et al. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia. Sci Rep. 2019;9(1):4634.
5. Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541-1552.
6. Schwab C, Harrison CJ. Advances in B-cell precursor acute lymphoblastic leukemia genomics. Hemasphere. 2018;2(4):e53.
7. Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524-2539.
8. Pieters R, De Groot-Kruseman H, Van Der Velden V, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34(22):2591-2601.
9. Naderi EH, Skah S, Ugland H, et al. Bone marrow stroma- derived PGE2 protects BCP-ALL cells from DNA damage- induced p53 accumulation and cell death. Mol Cancer. 2015;14(1):1-12.
10. Polak R, De Rooij B, Pieters R, Den Boer ML. B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment. Blood. 2015;126(21):2404-2414.
11. Usmani S, Sivagnanalingam U, Tkachenko O, Nunez L, Shand JC, Mullen CA. Support of acute lymphoblastic leukemia cells by nonmalignant bone marrow stromal cells. Oncol Lett. 2019;17(6):5039-5049.
12. Duan CW, Shi J, Chen J, et al. Leukemia propagating cells rebuild an evolving niche in response to therapy. Cancer Cell. 2014;25(6):778-793.
13. Portale F, Cricrì G, Bresolin S, et al. ActivinA: a new leukemia- promoting factor conferring migratory advantage to B-cell
Center in Utrecht for their project input and help in (leu- kemic) sample processing. Special acknowledgment for the bio-informatics support from Alex Q. Hoogkamer. We also thank the Franciscus Vlietland Hospital in Schiedam for providing cord blood samples, and the MultiPlex Core Facility in the Center for Translational Immunology, Uni- versity Medical Center Utrecht for performing Luminex experiments.
Funding
This study was funded by the Pediatric Oncology Foundation Rotterdam (SKOCR) and the Oncode Institute in Utrecht.
Data-sharing statement
Prof. Monique L. den Boer (m.l.denboer@prinsesmaxima- centrum.nl) can be contacted for original data.
precursor-acute lymphoblastic leukemic cells. Haematologica.
2019;104(3):533-545.
14. De Rooij B, Polak R, Stalpers F, Pieters R, Den Boer ML.
Tunneling nanotubes facilitate autophagosome transfer in the
leukemic niche. Leukemia. 2017;31(7):1651-1654.
15. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the
behavior of normal hematopoietic progenitor cells. Science.
2008;322(5909):1861-1865.
16. Baryawno N, Przybylski D, Kowalczyk MS, et al. A cellular
taxonomy of the bone marrow stroma in homeostasis and
leukemia. Cell. 2019;177(7):1915-1932.
17. van den Berk LCJ, van der Veer A, Willemse ME, et al. Disturbed
CXCR4/CXCL12 axis in paediatric precursor B-cell acute
lymphoblastic leukaemia. Br J Haematol. 2014;166(2):240-249. 18. Smids C, Horje CSHT, Nierkens S, et al. Candidate serum
markers in early Crohn’s disease: predictors of disease course.
J Crohns Colitis. 2017;11(9):1090-1100.
19. van Iersel MP, Kelder T, Pico AR, et al. Presenting and exploring
biological pathways with PathVisio. BMC Bioinformatics.
2008;9:399.
20. Zaliova M, Stuchly J, Winkowska L, et al. Genomic landscape of
pediatric B-other acute lymphoblastic leukemia in a consecutive
European cohort. Haematologica. 2019;104(7):1396-1406. 21. Pastorczak A, Domka K, Fidyt K, Martyna P, Firczuk M.
Mechanisms of immune evasion in acute lymphoblastic
leukemia. Cancers (Basel). 2021;13(7):1536.
22. Mostafavi S, Yoshida H, Moodley D, et al. Parsing the interferon
transcriptional network and its disease associations. Cell.
2016;164(3):564-578.
23. Einav U, Tabach Y, Getz G, et al. Gene expression analysis
reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene. 2005;24(42):6367-6375.
24. Dander E, Palmi C, D’Amico G, Cazzaniga G. The bone marrow niche in B-cell acute lymphoblastic leukemia: the role of microenvironment from pre-leukemia to overt leukemia. Int J Mol Sci. 2021;22(9):4426.
25. Schreiber G. The molecular basis for differential type I
Haematologica | 109 July 2024
2083